west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "恶性胸腔积液" 14 results
  • Systematic Review of Mannatide plus Cisplatin Treating Malignant Pleural Effusion

    【摘要】 目的 采用循证医学的方法评价甘露聚糖肽联合顺铂对比单用顺铂治疗恶性胸腔积液的有效性和安全性。 方法 计算机检索中国生物医学文献数据库、中国期刊全文数据库、中文科技期刊全文数据库、万方数据库,收集甘露聚糖肽联合顺铂对比单用顺铂治疗恶性胸腔积液的随机对照试验,检索时间为各数据库建库至2011年3月。对文献进行质量评价,用RevMan 5.0软件对数据进行Meta分析。 结果 共纳入6项研究,所有文献质量均为C级。共收入388例患者,Meta分析结果显示甘露聚糖肽联合顺铂组与单用顺铂组相比,总有效率前者高于后者,差异有统计学意义(Plt;0.05);消化道不良反应发生率两组组间差异无统计学意义(P=0.05);骨髓抑制发生率前者低于后者,差异有统计学意义(Plt;0.05);Karnofsky评分提高率前者高于后者,差异有统计学意义(Plt;0.05)。 结论 系统评价表明,甘露聚糖肽联合顺铂治疗恶性胸腔积液的疗效优于单用顺铂的方案。【Abstract】 Objective To assess the clinical efficacy and safety of mannatide plus cisplatin treating malignant pleural effusion. Methods Literatures were retrieved from CBM, VIP, CNKI, Wanfang databases by computer. Literatures were enrolled according to inclusion and exclusion criteria, and the quality of studies was evaluated according to the Cochrane Library handbook. The period duration of searching was between the establishment of the databases and March, 2011. Meta-analysis was conducted by RevMan 5.0 software. Results The meta-analysis of 6 included RCT, all ranked C, which involved 388 patients. The Meta-analysis showed that the total effective rate in mannatide plus cisplatin group significantly differed from that in cisplatin group (P<0.05). There were no significant difference in the adverse reaction of digestive tract between the two intervention groups (P=0.05). The adverse reaction of marrow depression inmannatide plus cisplatin group was much lower than that in cisplatin group (P<0.05). The increase of KPS in mannatide plus cisplatin group was higher than that in cisplatin group (P<0.05). Conclusions The analysis indicates mannatide plus cisplatin has a better effect on malignant pleural effusion than single cisplatin. However, the reliability of this review is affected by poor quality of included studies, and large-scale randomized controlled trials of high quality are needed to confirm the conclusions above.

    Release date:2016-08-26 02:18 Export PDF Favorites Scan
  • 隧道式胸腔引流管在恶性胸腔积液患者中的应用

    摘要: 目的 介绍隧道式胸腔引流管(tunnelled pleural catheter,TPC)治疗恶性胸腔积液(MPE)的方法,探讨其临床应用价值。 方法 分析美国西南医学中心St.Paul医院自2002年10月至2005年11月共对112例MPE患者植入TPC的临床资料,其中男69例,女43例;年龄58.5±6.7岁。主要原发病为原发性肺癌、转移性肺肿瘤(原发癌为淋巴瘤、乳腺癌、卵巢癌)、胸膜间皮瘤;分析MPE患者TPC植入的效果。 结果 在3年观察期内,112例MPE患者共应用125例次TPC治疗,其中10例为对侧植入TPC,4例为同侧再次植入TPC。随访2周后有48例次症状完全缓解,62例次症状部分缓解,5例次症状未缓解,有5例次植管失败,5例次TPC植入术后2周内失去随访。 120例次成功植入TPC患者中有51例发生继发性胸膜炎,仅5例在管道拔除后需要再次胸腔治疗。随访2周中单胸腔积液量lt;20%。导管留置时间平均为56 d。所有TPC植入术后患者随访期的生存时间平均为144 d,随访1个月和1年的病死率分别为128%和836%。 结论 对具有门诊治疗条件、需要姑息治疗的MPE患者,TPC是有效的方法之一。

    Release date:2016-08-30 06:03 Export PDF Favorites Scan
  • 电视纵隔镜在恶性胸腔积液诊治中的应用

    目的探讨电视纵隔镜在诊治恶性胸腔积液中的应用价值。方法回顾分析自2003年10月至2004年4月12例恶性胸腔积液患者行电视纵隔镜胸膜活检+滑石粉胸膜固定术治疗的临床资料。结果术后病理诊断腺癌8例,鳞癌4例;肺癌胸膜转移11例,食管癌肺、胸膜转移1例;手术诊断率100%,有效率91.7%(11/12),全组无手术死亡。术后发生低热3例,经处理后退热;胸痛3例,经止痛后缓解。结论电视纵隔镜对恶性胸腔积液的诊断和治疗有良好的临床效果。

    Release date:2016-08-30 06:26 Export PDF Favorites Scan
  • A Clinical Study on Arsenic Trioxide Combined with Cisplatin in the Treatment of Malignant Pleural Effusion

    目的 观察三氧化二砷联合顺铂腔内注射治疗恶性胸腔积液的疗效和毒副反应。 方法 2011年9月-2012年9月,将恶性胸腔积液患者60例,随机分为治疗组和对照组,每组各30例。在胸腔积液充分引流后,治疗组胸腔内注射三氧化二砷20 mg联合顺铂60 mg;对照组只给予胸腔灌注顺铂60 mg,胸腔灌注化学疗法药物两组均1次/周,共3次。观察疗效及不良反应。 结果 治疗组和对照组的有效率分别为93.3%和56.7%(P<0.05)。治疗组和对照组的一般状况改善率分别为70.0%和40.0%(P<0.05)。两组的不良反应相近。 结论 三氧化二砷联合顺铂腔内注射治疗恶性胸腔积液具有协同增效作用,不良反应小。

    Release date: Export PDF Favorites Scan
  • The Expression of Aldolase A in Malignant Pleural Effusion and Its Relationship with Carcinoembryonic Antigen and Lactate Dehydrogenase

    ObjectiveTo investigated the levels of aldolase A (ALDOA) in pleural effusion in patients with different pathological types of lung cancer and patients with tuberculous pleurisy,and the correlation between ALDOA and carcinoembryonic antigen (CEA),lactate dehydrogenase(LDH). Methods80 cases of pleural effusion samples were collected,of which 65 cases of lung cancer (malignant group) and 15 cases of tuberculous pleurisy (TB group). All the patients were not treated with anti-inflammatory or steroid therapy. ALDOA concentrations in pleural effusion were detected by ELISA and the contents of CEA and LDH in pleural fluid were detected by chemiluminescence assay. ResultsThe levels of ALDOA,CEA and LDH in the malignant group were 46.75±21.39 ng/mL,82.24±56.63 ng/mL,755.76±382.54 U/L respectively,and were 23.92±17.21 ng/mL,2.55±1.67 ng/mL,and 388.37±163.87 U/L in the TB group respectively. The levels of ALDOA,CEA and LDH in the malignant group were significantly higher than those in the TB group (P<0.01). The concentrations of ALDOA in malignant pleural effusion from different pathological types of lung cancer were 71.65±32.09 ng/mL(adenocarcinoma),22.43±18.23 ng/mL(small cell lung cancer),and 19.16±13.85 ng/mL(squamous cell carcinoma),respectively. The concentration of ALDOA in malignant pleural effusion from the adenocarcinoma patients was significantly higher than that in the other two types (P<0.05). The concentration of CEA was 112.40±62.71 ng/mL(adenocarcinoma),62.45±54.78 ng/mL(small cell lung cancer),and 71.87±52.4 ng/mL(squamous cell carcinoma),respectively. It was significantly higher in adenocarcinoma than that in other two types (P<0.05). The levels of LDH were 661.81±328.93 U/L(adenocarcinoma),737.62±315.41 U/L(small cell lung cancer),767.85±503.28 U/L(squamous cell carcinoma),respectively. There was no significant difference in three types(P>0.05). The concentrations of ALDOA in pleural effusion from the patients with lung cancer or tuberculous pleurisy were positively correlated with the concentrations of CEA and LDH (P<0.01 or 0.05). ConclusionThe levels of ALDOA,CEA and LDH in malignant pleural effusion from lung cancer patients were significantly higher than those in pleural effusion from patients with tuberculous pleurisy. The ALDOA and CEA levels in malignant pleural effusion from lung adenocarcinoma patients were significantly higher than those in small cell lung cancer and squamous cell carcinoma patients. There were highly positive correlation between ALDOA,CEA and LDH levels.

    Release date: Export PDF Favorites Scan
  • 电视胸腔镜手术治疗恶性胸腔积液37例临床分析

    目的探讨电视胸腔镜手术治疗恶性胸腔积液的方法,总结其临床经验。 方法回顾性分析2009年1月至2011年12月宝鸡市中心医院37例恶性胸腔积液患者的临床资料, 男21例、女16例, 年龄43~75岁。其中肺癌15例,乳腺癌7例,食管癌7例,胃癌4例,胸膜间皮瘤3例,卵巢癌1例;均为单侧胸腔积液,其中左侧胸腔积液22例, 右侧胸腔积液15例。所有患者均行电视胸腔镜手术(VATS)或VATS辅助小切口完成手术,在电视胸腔镜下行胸膜剥脱术,并喷洒滑石粉固定胸膜。 结果围术期无死亡,7例(18.9%)延长切口,手术时间(40.32±19.06)min,术中出血量(90.09±41.03)ml,术后(7.31±2.08)d拔除胸腔引流管,术后住院时间(9.02±3.11)d。手术有效率100%,其中完全缓解19例(51.4%)。术后出现轻度并发症,如肺部感染、持续性漏气和切口感染等, 经对症处理治愈。 结论电视胸腔镜治疗恶性胸腔积液是一种微创、有效、实用的治疗方法。

    Release date: Export PDF Favorites Scan
  • Brucea Javanica Oil Emulsion in Treatment of Malignant Pleural Effusion: A Meta-Analysis

    ObjectiveTo systematically review the efficacy and safety of brucea javanica oil emulsion with/without cisplatin in the treatment of malignant pleural effusion (MPE). MethodsWe electronically search PubMed, The Cochrane Library (Issue 6, 2013), EMbase, CBM, WanFang Data, VIP and CNKI to collect randomized controlled trial about brucea javanica oil emulsion for MPE from the establishment dates to June 2013. According to the inclusion and exclusion criteria, two reviewers independently screened literature, extracted data, and assessed the methodological quality of included studies. Then meta-analysis was performed using RevMan 5.1 software. ResultsA total of twenty-five RCTs involving 1 620 patients were included. The results of meta-analysis showed that:compared with using cisplatin alone, brucea javanica oil emulsion plus cisplatin could improve clinical efficiency (RR=1.45, 95%CI 1.34 to 1.57, P < 0.000 01) and patients' quality of life (RR=1.36, 95%CI 1.18 to 1.56, P < 0.000 1), and relieved the incidences of bone marrow depression (OR=0.31, 95%CI 0.22 to 0.42, P < 0.000 01) and digestive tract reaction (OR=0.36, 95%CI 0.24 to 0.54, P < 0.000 01, ) and fever (OR=0.18, 95%CI 0.08 to 0.40, P < 0.000 1). ConclusionCurrent evidence indicates that brucea javanica oil emulsion could improve chemotherapy effects MPE. However, due to the limited quality of the included studies, more high quality studies with large sample size are needed to verify the conclusion.

    Release date: Export PDF Favorites Scan
  • Diagnostic Value of Neuron Specific Enolase for Malignant Pleural Effusion: A Meta-Analysis

    ObjectiveTo systematically review the diagnostic value of neuron specific enolase (NSE) for malignant pleural effusion. MethodsWe comprehensively searched databases including The Cochrane Library (Issue 1, 2012), EMbase, MEDLINE, CBM, CNKI, WanFang Data and VIP from inception to January 2012 to collect studies about the diagnostic value of NSE for malignant pleural effusion. Literature screening according to the inclusion and exclusion criteria, data extraction and methodological quality assessment were completed by two reviewers independently. Then Meta-DiSc software (version 1.4) was used for pooling analysis. ResultsA total of 12 studies were finally included. The results of meta-analysis showed that the value of pooled specificity, sensitivity, positive likelihood radio, negative likelihood radio and diagnostic odds ratio (DOR) were 0.79 (0.76 to 0.84), 0.55 (0.51 to 0.59), 3.2 (1.94 to 5.29), 0.58 (0.45 to 0.74), 7.56 (3.74 to 15.30), respectively; and the area under SROC curve (AUC) was 0.813 1. ConclusionUsing NSE as a maker to diagnose malignant pleural effusion is of certain clinical value, which is used to differentiate benign and malignant pleural effusion.

    Release date: Export PDF Favorites Scan
  • Efficacy and Safety of Endostar Combined with Cisplatin in Treatment of Non-Small Cell Lung Cancer with Malignant Pleural Effusion: A Meta-analysis

    ObjectiveTo systematically review the efficacy and safety of intrapleural injection of endostar combined with cisplatin in treatment of non-small cell lung cancer (NSCLC) with malignant pleural effusion. MethodsDatabases including PubMed, The Cochrane Library (Issue 2, 2016), EMbase, Web of Science, CNKI, VIP and WanFang Data were searched to collect randomized controlled trials (RCTs) about endostar combined with cisplatin for NSCLC with malignant pleural effusion from inception to February 2016. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then meta-analysis was performed by using RevMan 5.3 software. ResultsA total of 10 RCTs involving 610 patients were finally included. The results of meta-analysis showed that: The overall response rate and the improvement rate of quality of life in the endostar combined with cisplatin group were higher than that of the cisplatin alone group (RR=1.71, 95%CI 1.49 to 1.95, P<0.00001; RR=1.68, 95%CI 1.44 to 1.96, P<0.00001, respectively). However, There were no significant differences between two groups in incidence of gastrointestinal reaction, incidence of leucopenia and incidence of thrombocytopenia (all P values>0.05). ConclusionCompared with cisplatin, intrapleural injection of endostar combined with cisplatin can improve the overall response rate and improve the quality of life of NSCLC patients with malignant pleural effusion. Due to the limited quality and quantity of included studies, more high quality studies are needed to verify the above conclusion.

    Release date: Export PDF Favorites Scan
  • Clinical efficacy of pleural infusion chemotherapy with docetaxel in treating malignant pleural effusion

    Objective To evaluate the clinical efficacy and safety of pleural infusion chemotherapy with docetaxel in the treatment of malignant pleural effusion. Methods Twenty-three patients with malignant tumor confirmed by biopsy or postoperative pathology, complicated with malignant pleural effusion confirmed by exfoliative cytology, were treated between March 2013 and June 2014. All the 23 patients underwent thoracic puncture and catheter drainage for the removal of contraindications for chemotherapy. Then, pleural infusion chemotherapy was performed with docetaxel (40 mg/m2), normal saline (250 mL) and dexamethasone (10 mg), 21 days as a cycle. Before pleural infusion chemotherapy with docetaxel, all the patients were given standard pretreatment with dexamethasone, cimetidine/ranitidine or promethazine. The efficacy and safety of the treatment were evaluated in each cycle. Results Among the 23 selected patients, 6 were evaluated as complete remission and 11 as partial remission, with an effective rate of 73.91%. All the patients had acceptable tolerance in the process of the treatment. The most common side effects were bone marrow suppression (78.26%), and nausea and vomiting (82.61%). No such complications as allergy, fluid retention, cardiac toxicity or degree-Ⅳ adverse reactions were detected. Conclusion Pleural infusion chemotherapy with docetaxel in the treatment of malignant pleural effusion is effective with mild adverse reactions, which is worthy to be popularized.

    Release date:2017-01-18 08:50 Export PDF Favorites Scan
2 pages Previous 1 2 Next

Format

Content